CAH, LITE Earnings; Home Sales Dip: Aug. 11 Roundup

Cardinal Health topped fiscal 2026 targets and issued above-consensus FY2027 guidance; Lumentum's optical components revenue doubled on AI demand; existing home sales slipped 1.7% in July.

CAH non-GAAP EPS surged 40% to $2.91 in Q4, full-year FY2026 revenue reached $254.2B; FY2027 EPS midpoint of $12.50 beats consensus by 3.8%.
LITE Q4 revenue hit $1.01B, up 109% YoY, as AI data-center buildout drove record demand for optical components; Q1 guidance set at ~$1.25B.
July existing home sales fell to a 4.06M annual pace; median price rose 2.0% to $434,100 — the 37th consecutive month of year-over-year gains.

Lead

Three high-profile data points landed Monday, August 11, painting a varied picture of U.S. corporate and economic momentum. Cardinal Health posted blockbuster fiscal 2026 results and set a FY2027 earnings target that surpassed Wall Street, lifting shares toward all-time highs. Lumentum Holdings revealed that demand for optical components tied to artificial-intelligence infrastructure essentially doubled its top line in a single year. And the National Association of Realtors reported that existing home sales retreated 1.7% in July to a seasonally adjusted annual rate of 4.06 million — still 0.7% above year-ago levels — as mortgage rates climbed.

Cardinal Health: Pharmaceutical Distribution at Scale

Cardinal Health (CAH) reported Q4 fiscal 2026 non-GAAP diluted EPS of $2.91, up 40% from $2.08 a year earlier and well ahead of the $2.42 analyst consensus — a 20% beat. Fourth-quarter revenue of $63.7 billion grew 6% year over year, with the Pharmaceutical and Specialty Solutions segment — the heart of the company's pharmaceutical distribution franchise — contributing $58.85 billion, a 6.3% gain. The Global Medical Products and Distribution unit posted $3.13 billion, down 2.2%.

For the full fiscal year 2026, revenue reached $254.2 billion, a 14% increase, while non-GAAP EPS of $11.26 represented 37% growth. Non-GAAP operating earnings for the year rose 30% to $3.6 billion, with profit growth recorded across all five business segments.

The forward-looking signal proved equally powerful. Management guided fiscal 2027 non-GAAP EPS to $12.40–$12.60, implying 13%–15% growth. The $12.50 midpoint sits 3.8% above the prior $12.04 consensus. Shares advanced 3.6% to $245.64 in morning trade, approaching an all-time high, as investors read the guidance as confirmation that Cardinal's scale advantages in pharmaceutical distribution are compounding steadily.

Lumentum: Optical Components Ride the AI Supercycle

Lumentum Holdings (LITE) delivered one of the technology sector's starkest year-over-year comparisons. Q4 fiscal 2026 net revenue of $1.01 billion — the company's first billion-dollar quarter — represented 109% growth, fueled overwhelmingly by hyperscale data-center customers racing to connect AI clusters with high-bandwidth fiber links. Adjusted EPS of $3.23 exceeded expectations, and non-GAAP gross margin expanded to 50.4%, demonstrating that the scale benefits of surging optical components volumes are flowing through to profitability.

For the full fiscal year 2026, Lumentum generated revenue of $3.01 billion, up 83.2% from $1.6 billion in FY2025. Non-GAAP net income reached $782.3 million, or $8.67 per diluted share, compared with $146.4 million and $2.06 per share in the prior year.

Management guided Q1 FY2027 revenue to approximately $1.25 billion, implying further sequential acceleration. An additional structural tailwind emerged in recent weeks: the Trump administration signaled plans to bar newly manufactured Chinese optical transceivers from U.S. data centers, a policy move that could redirect large procurement volumes toward domestic suppliers of optical components such as Lumentum. Shares had already rallied roughly 131% year-to-date ahead of the print, having risen 6% in the prior session alone on the transceiver policy news.

Housing: Inventory Constraint Persists Despite Rate Dip

The NAR's July report illustrated the durable tension between affordability and limited supply that has characterized U.S. residential real estate since 2022. Existing home sales of 4.06 million (SAAR) declined 1.7% from June but remained fractionally above the July 2025 pace. The national median price of $434,100 rose 2.0% year over year — the 37th consecutive month of annual appreciation.

Inventory ticked down to 1.54 million units, equating to 4.6 months of supply at the current sales rate. The average 30-year fixed mortgage rate rose to 6.54% in July from 6.49% in June, trimming affordability at the margin. First-time buyers accounted for 29% of transactions, up one percentage point year over year but down from 33% in June. Year-to-date 2026 sales remain 2.4% ahead of the comparable 2025 period, suggesting the full-year trajectory is modestly positive despite monthly volatility.

Outlook

Cardinal Health's FY2027 earnings guidance positions the pharmaceutical distribution leader for another year of double-digit profit growth, underwriting its case as a defensive compounder in a volatile macro environment. Lumentum's sequential revenue acceleration into Q1 FY2027 indicates that AI-infrastructure capital expenditure has not yet peaked, sustaining the multi-year demand cycle for advanced optical components. The housing market, meanwhile, faces a self-reinforcing supply constraint: moderate price appreciation continues to deter would-be sellers locked into sub-4% mortgages, keeping inventory lean and preventing the price correction that might clear affordability hurdles for first-time buyers.